{
  "report_rows": [
    {
      "kpi": "Q4 FY2026 revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.475B vs. cons $1.466B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q4 FY2026 non-GAAP diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.92 vs. cons $2.88",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q4 FY2026 non-GAAP gross margin",
      "prediction": "IN-LINE",
      "answer": "pred ~62.9% vs. cons 62.8%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2027 reported revenue outlook, including MatrixCare divestiture and Noctrix",
      "prediction": "BETTER",
      "answer": "guide ~$5.95B vs. cons $5.89B (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2027 non-GAAP diluted EPS outlook",
      "prediction": "BETTER",
      "answer": "guide ~$12.15 vs. cons $12.03 (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2027 non-GAAP gross-margin outlook",
      "prediction": "BETTER",
      "answer": "guide ~63.1% vs. cons 62.8% (FY2027)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A ~1.4% EPS beat versus consensus and FY2027 EPS guide of ~$12.15 versus ~$12.03 support upward out-period revisions despite the ~$0.20 Noctrix dilution and MatrixCare revenue removal.",
  "day5_confidence": "MEDIUM"
}